ABSTRACT
FDG-PET scan is able to provide valuable information, when CT or MR findings are ambigu ous; FDG-PET should be coupled with CT to combine metabolic and morphological data.
physical and pharmaceutical treatments. “Objective” tumor shrinkage-widely adopted as a standard end-point for selecting new anticancer drugs and as a prospective end-point for clinical trials designed to estimate the benefit of a treatment in a specific group of patients-is amply used in everyday clinical practice to guide clinical decision-making.1
